Sanofi-Regeneron's Praluent cuts cholesterol in Odyssey trials

PARIS (Reuters) - France's Sanofi and partner Regeneron Pharmaceuticals said on Sunday their anti-cholesterol drug Praluent recorded positive results in its first dedicated studies involving patients with diabetes and high cholesterol.